{"id":37323,"date":"2026-01-30T11:42:53","date_gmt":"2026-01-30T10:42:53","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=37323"},"modified":"2026-01-30T14:07:17","modified_gmt":"2026-01-30T13:07:17","slug":"ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/","title":{"rendered":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)"},"content":{"rendered":"\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

Nantes, France, January 21, 2026 \u2013 6pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173;<\/p>\n\n\n\n

Mnemo: OSE), today acknowledges the announcement by its partner Veloxis Pharmaceuticals, Inc.<\/p>\n\n\n\n

that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to<\/p>\n\n\n\n

pegrizeprument (VEL-101) for the prevention of organ rejection in patients undergoing liver<\/p>\n\n\n\n

transplantation<\/p>\n\n\n\n


To know more<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal
\nantibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis
\nin 2021 for all transplant-related indications. Veloxis is responsible for the global development,
\nmanufacturing, and future commercialization of the product.<\/p>\n","protected":false},"author":6,"featured_media":37322,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32,18],"tags":[],"class_list":["post-37323","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members","category-uncategorized"],"yoast_head":"\nOSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - MabDesign<\/title>\n<meta name=\"description\" content=\"OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal antibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis in 2021 for all transplant-related indications. Veloxis is responsible for the global development, manufacturing, and future commercialization of the product.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - MabDesign\" \/>\n<meta property=\"og:description\" content=\"OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal antibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis in 2021 for all transplant-related indications. Veloxis is responsible for the global development, manufacturing, and future commercialization of the product.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T10:42:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T13:07:17+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"247\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Maissa Pote\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maissa Pote\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/\"},\"author\":{\"name\":\"Maissa Pote\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\"},\"headline\":\"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)\",\"datePublished\":\"2026-01-30T10:42:53+00:00\",\"dateModified\":\"2026-01-30T13:07:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/\"},\"wordCount\":65,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/\",\"name\":\"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png\",\"datePublished\":\"2026-01-30T10:42:53+00:00\",\"dateModified\":\"2026-01-30T13:07:17+00:00\",\"description\":\"OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal antibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis in 2021 for all transplant-related indications. Veloxis is responsible for the global development, manufacturing, and future commercialization of the product.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png\",\"width\":1280,\"height\":247},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\",\"name\":\"Maissa Pote\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"caption\":\"Maissa Pote\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/communication\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - MabDesign","description":"OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal antibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis in 2021 for all transplant-related indications. Veloxis is responsible for the global development, manufacturing, and future commercialization of the product.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/","og_locale":"en_US","og_type":"article","og_title":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - MabDesign","og_description":"OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal antibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis in 2021 for all transplant-related indications. Veloxis is responsible for the global development, manufacturing, and future commercialization of the product.","og_url":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/","og_site_name":"MabDesign","article_published_time":"2026-01-30T10:42:53+00:00","article_modified_time":"2026-01-30T13:07:17+00:00","og_image":[{"width":1280,"height":247,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png","type":"image\/png"}],"author":"Maissa Pote","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Maissa Pote","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/"},"author":{"name":"Maissa Pote","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029"},"headline":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)","datePublished":"2026-01-30T10:42:53+00:00","dateModified":"2026-01-30T13:07:17+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/"},"wordCount":65,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/","url":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/","name":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png","datePublished":"2026-01-30T10:42:53+00:00","dateModified":"2026-01-30T13:07:17+00:00","description":"OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal antibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis in 2021 for all transplant-related indications. Veloxis is responsible for the global development, manufacturing, and future commercialization of the product.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/Logo-Ose_Immunotherapeutics.svg.png","width":1280,"height":247},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029","name":"Maissa Pote","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","caption":"Maissa Pote"},"url":"https:\/\/mabdesign.fr\/en\/author\/communication\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=37323"}],"version-history":[{"count":2,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37323\/revisions"}],"predecessor-version":[{"id":37349,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37323\/revisions\/37349"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/37322"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=37323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=37323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=37323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}